Fredericton-based LuminUltra Technologies, which specializes in biological tests, has acquired GL Biocontrol, a French provider of microbial testing and risk management services for municipal and industrial water systems.

Headquartered in Montpellier, GL Biocontrol has worked with more than 500 municipalities and industrial operators across Europe. The company has been a key player in advancing microbial monitoring practices in France, particularly through the adoption of second-generation adenosine triphosphate, or ATP, testing. Its services cover areas such as drinking water safety, Legionella prevention, and water reuse.

The acquisition – the terms of which were not disclosed – will allow GL Biocontrol to maintain its brand and operations while gaining access to LuminUltra’s broader product portfolio, infrastructure, and scientific resources. GL Biocontrol’s Montpellier office will also serve as LuminUltra’s European headquarters, offering the New Brunswick company a beachhead for further European expansion.

“France has long been at the forefront of water technology and microbiological innovation,” said LuminUltra CEO Pat Whalen in a statement. “This acquisition brings together two science-led organizations committed to advancing that leadership.”

GL Biocontrol combines diagnostic testing with software tools, technical consulting, and training to help clients manage microbial risks. Its work includes risk assessments, system mapping, and developing control strategies to safeguard public health and infrastructure.

“With the evolving European Drinking Water Directive and the rise of water safety plans, utilities need faster, more dependable tools,” said Celia Martinez, president of GL Biocontrol. “We’ve positioned second-generation ATP as a frontline indicator, helping operators anticipate risks, optimize control strategies, and protect water quality over the long term.”

With this deal, LuminUltra has now made eight acquisitions in eight years in keeping with its strategy to expand its portfolio of microbial risk management solutions. In July 2024, LuminUltra bought the legionella-testing assets of Genomadix Inc, along with rights to develop and commercialize further assays and test methods in water, energy and food and beverage markets.

The company said GL Biocontrol strengthens its position in Europe while providing a base for further growth in the region.

Whalen said the addition of GL Biocontrol fits with LuminUltra’s long-term plan to expand internationally while maintaining a focus on microbial safety. “This acquisition reinforces our long-term vision,” he said. “With GL Biocontrol now part of the organization, the company is better positioned to invest in R&D, expand globally, and raise standards in microbial risk management.”